Annexon (NASDAQ:ANNX) highlighted progress across three programs targeting the classical complement pathway during a fireside ...

Lead antibody MB0109 targets C1q and uniquely inhibits both classical complement cascade and C1q-mediated macrophage/microglial activation — two key drivers of neuroinflammationMB0109 demonstrated ...

Creative Biolabs expands its research capabilities, offering diversified tools and services to support global biomedical innovation. SHIRLEY, NY, UNITED STATES, February 27, 2026 /EINPresswire.com/ — ...

Below, we’ve brought together the month’s themes in our new Trends Outside the Headlines, trends & insights report, ...

A replay of the webcast will be archived on the Annexon website for 30 days following the presentation. Annexon Biosciences (Nasdaq: ANNX) is advancing the next generation platform of targeted ...

Chennai: People whose immune systems mount an unusually aggressive early response to tuberculosis may be less likely to ...

Opportunities in the C5 inhibitors market include developing next-gen biosimilars and biosuperiors to improve administration frequency and expand treatment indications for diseases like aHUS, SCD, MG, ...

-- The unmet need and current treatment landscape for GA -- The mechanism of disease and role of C1q -- Vonaprument, Annexon's neuroprotective C1q inhibitor with the potential to be the first targeted ...

“ In a Landscape: Classical Music in the Wild,” the outdoor classical music series known for staging piano concerts in natural and scenic settings, has released an early look at its upcoming tour.

The Model Acute Pathway provides evidence‑based standards to improve care during the first 72 hours of hospital care. Developed in partnership with the Royal College of Physicians, the Society for ...

Geographic atrophy (GA) is a severe form of age-related macular degeneration with limited treatment options, affecting millions worldwide. Recent FDA-approved therapies, pegcetacoplan and avacincaptad ...